Cosette Pharmaceuticals Launches First Injectable Product - Prochlorperazine Edisylate Injection in the U.S.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Launch Further Diversifies Cosette’s Product Offerings In-Line with Growth Strategy

Prochlorperazine Edisylate (Photo: Business Wire)
“This is the first injectable product Cosette has marketed in the
Prochlorperazine Edisylate Injection 10mg/2ml (5mg/ml) is the generic equivalent for Compazine® Injection 10mg/2ml (5mg/ml). According to IQVIA®, annual sales for Prochlorperazine Edisylate for 12 months ended
Prochlorperazine Edisylate is used to control severe nausea and vomiting. Prochlorperazine Edisylate is also used for the treatment of schizophrenia. See Boxed Warning: WARNINGS. See Package Insert (PI) for full prescribing information including Safety Information:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4687b9f5-2d67-4fe0-af4d-2415a42b5292&audience=consumer
About
injectables. Cosette has a long history of quality manufacturing, consistent supply, and commercialization success, including two sites (
For more information, please visit: www.cosettepharma.com and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220222005360/en/
Media:
Source: